Want to see INAB full AI Analyst Report?
Top Page
IN8bio
(NASDAQ:INAB)
Select Model
Select Model
Rating:47Neutral
Price Target:
$1.00
▼(-15.25% Downside)
Action:Reiterated
Date:10/02/26
The score is primarily held down by weak financial fundamentals (no revenue, ongoing losses and cash burn with declining equity), despite some improvement in loss/burn trends and low leverage. Technicals are moderately supportive in the near term (positive momentum and above key short/medium-term averages), but valuation remains challenging due to negative earnings and no dividend support.
Positive Factors
Engineered gamma-delta T-cell platform
IN8bio has a focused therapeutic platform spanning autologous and allogeneic gamma-delta T-cell approaches, with applications across blood cancers, solid tumors, and brain cancers. This breadth creates multiple clinical development pathways from a common technology base.
Negative Factors
No product revenue
The absence of revenue means IN8bio has not yet demonstrated commercial product demand or an internally funded business model. Its financial outlook therefore remains tied to clinical progress and eventual commercialization rather than an established recurring revenue base.
Read all positive and negative factors
Positive Factors
Negative Factors
Engineered gamma-delta T-cell platform
IN8bio has a focused therapeutic platform spanning autologous and allogeneic gamma-delta T-cell approaches, with applications across blood cancers, solid tumors, and brain cancers. This breadth creates multiple clinical development pathways from a common technology base.
Read all positive factors
IN8bio (INAB) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$10.35M
Dividend YieldN/A
Average Volume (3M)45.46K
Price to Earnings (P/E)―
Beta (1Y)1.63
Revenue GrowthN/A
EPS Growth81.87%
CountryUS
Employees18
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)-1.87
Shares Outstanding9,858,383
10 Day Avg. Volume33,158
30 Day Avg. Volume45,458
Financial Highlights & Ratios
PEG Ratio<0.01
Price to Book (P/B)0.37
Price to Sales (P/S)0.00
P/FCF Ratio-0.81
Enterprise Value/Market Cap1.13
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit-23.34
Enterprise Value/Ebitda-0.70
Forecast
1Y Price Target
$5.50Price Target Upside366.10% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering2
EPS Forecast (FY)-1.11
Revenue Forecast (FY)N/A
IN8bio Business Overview & Revenue Model
Company Description
IN8bio, Inc. is a biotechnology firm currently in the clinical trial phase, dedicated to identifying, advancing, and bringing to market gamma-delta T cell-based treatments specifically for various forms of cancer. The company's primary therapeutic...
IN8bio Financial Statement Overview
Summary
Income Statement
12
Very Negative
Balance Sheet
48
Neutral
Cash Flow
22
Negative
| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit | -500.00K | -2.50M | 0.00 | -2.50M | 0.00 | 0.00 |
| EBITDA | -16.71M | -16.94M | -26.94M | -27.51M | -27.42M | -13.87M |
| Net Income | -18.67M | -19.44M | -30.44M | -30.01M | -28.52M | -14.65M |
Balance Sheet | ||||||
| Total Assets | 21.75M | 32.28M | 20.94M | 33.71M | 33.04M | 42.22M |
| Cash, Cash Equivalents and Short-Term Investments | 17.96M | 27.09M | 11.12M | 21.28M | 18.18M | 37.02M |
| Total Debt | 2.18M | 2.78M | 5.03M | 4.89M | 5.87M | 2.41M |
| Total Liabilities | 3.38M | 4.72M | 6.47M | 8.77M | 10.31M | 4.04M |
| Stockholders Equity | 18.36M | 27.56M | 14.48M | 24.94M | 22.73M | 38.18M |
Cash Flow | ||||||
| Free Cash Flow | -14.60M | -12.71M | -24.25M | -23.94M | -27.83M | -13.82M |
| Operating Cash Flow | -14.36M | -12.71M | -24.15M | -23.34M | -24.12M | -13.51M |
| Investing Cash Flow | -242.00K | 0.00 | -187.00K | -600.00K | -3.71M | -309.00K |
| Financing Cash Flow | 19.23M | 28.64M | 14.18M | 27.04M | 8.99M | 32.95M |
IN8bio Technical Analysis
Negative
1.18
Price Trends
1.17
Negative
1.23
Negative
1.49
Negative
Market Momentum
-0.04
Positive
39.85
Neutral
13.25
Positive
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For INAB, the sentiment is Negative. The current price of 1.18 is below the 20-day moving average (MA) of 1.24, above the 50-day MA of 1.17, and below the 200-day MA of 1.49, indicating a bearish trend. The MACD of -0.04 indicates Positive momentum. The RSI at 39.85 is Neutral, neither overbought nor oversold. The STOCH value of 13.25 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for INAB.
IN8bio Risk Analysis
IN8bio disclosed 74 risk factors in its most recent earnings report. IN8bio reported the most risks in the "Tech & Innovation" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
IN8bio Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
48 Neutral | $4.03M | -1.45 | -40.62% | ― | 33.30% | 40.59% | |
47 Neutral | $10.35M | -0.56 | -91.18% | ― | ― | 81.87% | |
47 Neutral | $8.07M | -0.27 | -304.87% | ― | ― | 98.98% | |
44 Neutral | $6.52M | -0.48 | -46.72% | ― | -99.38% | 53.42% |
* Healthcare Sector Average
INAB
IN8bio
1.05
-1.05
-50.00%
ERNA
Eterna Therapeutics
2.07
-27.69
-93.06%
QNRX
Quoin Pharmaceuticals
4.02
-9.18
-69.55%
XBIO
Xenetic Biosciences
1.72
-2.03
-54.13%
APRE
Aprea Therapeutics
0.52
-0.82
-61.42%
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.